Literature DB >> 21270747

Hodgkin's lymphoma: the role of cell surface receptors in regulation of tumor cell fate.

M Yurchenko1, S P Sidorenko.   

Abstract

UNLABELLED: The hallmark of Hodgkin's lymphoma (HL) are mononucleated Hodgkin's cells and multinucleated Reed-Sternberg (HRS) cells, which usually account for only about 1% of cells in the tumor tissue. The majority of HRS cells in classical HL are derived from germinal centre B cells that have acquired disadvantageous Ig variable chain gene mutations and escaped from apoptosis. Due to reprogramming of gene expression, these lymphoma cells have lost the expression of most B-cell specific genes and acquired expression of multiple genes that are typical for other hematopoietic cells. HRS cells attract various cells of immune system into lymphoma tissue resulting in an inflammatory microenvironment. Moreover, HRS cells are dependent on microenvironment, especially on survival signals from other cells. Despite the loss of BCR - the master-regulator of B cell fate, HRS cells express a number of receptors that regulate tumor cell survival. The rescue of HRS cells from apoptosis is a key event in HL pathogenesis. These cells express at least six receptors that belong to TNF receptor family: CD30, CD40, CD95, TACI, BCMA and RANK, co-stimulatory receptors CD80 and CD86, and E-selectins ligand CD15. Due to the mutations in genes encoding proteins of CD95-mediated apoptotic signaling pathway, it is not functional in HRS cells. Ligands of TNF family receptors on cells in HL microenvironment contribute to the activation of canonical and non-canonical NF-κB signaling pathways and survival program of HRS cells. Moreover, in HRS cells a number of multiple mutations in negative NF-κB regulators, and also gains and amplifications of positive regulators, cooperate in deregulating these pathways. All TNF receptors may be linked to the activation of prosurvival gene expression programs via Akt and ERK pathways. HRS cells also express CD150 receptor with specific ITSM motifs in the cytoplasmic tail. Ligation of this receptor on HRS cells induced activation of Akt and ERK pathways, and moreover, it triggered activation of JNK signaling cascade.
CONCLUSION: The review presents the current views on the role of cell surface receptors in maintenance of HL microenvironment favorable for HRS cells survival.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21270747

Source DB:  PubMed          Journal:  Exp Oncol        ISSN: 1812-9269


  6 in total

Review 1.  Regulatory roles of the tumor necrosis factor receptor BCMA.

Authors:  Christine M Coquery; Loren D Erickson
Journal:  Crit Rev Immunol       Date:  2012       Impact factor: 2.214

2.  Long-term hematopoietic stem cell damage in a murine model of the hematopoietic syndrome of the acute radiation syndrome.

Authors:  Hui Lin Chua; P Artur Plett; Carol H Sampson; Mandar Joshi; Rebeka Tabbey; Barry P Katz; Thomas J MacVittie; Christie M Orschell
Journal:  Health Phys       Date:  2012-10       Impact factor: 1.316

Review 3.  Emerging therapies provide new opportunities to reshape the multifaceted interactions between the immune system and lymphoma cells.

Authors:  M Pizzi; M Boi; F Bertoni; G Inghirami
Journal:  Leukemia       Date:  2016-06-08       Impact factor: 11.528

4.  Interleukin-2 Functions in Anaplastic Large Cell Lymphoma Cells through Augmentation of Extracellular Signal-Regulated Kinases 1/2 Activation.

Authors:  Masanori Ito; Nianxi Zhao; Zihua Zeng; Xiaobo Zhou; Chung-Che Chang; Youli Zu
Journal:  Int J Biomed Sci       Date:  2011-09

5.  Rescue of impaired NK cell activity in hodgkin lymphoma with bispecific antibodies in vitro and in patients.

Authors:  Katrin S Reiners; Jörg Kessler; Maike Sauer; Achim Rothe; Hinrich P Hansen; Uwe Reusch; Christian Hucke; Ulrike Köhl; Horst Dürkop; Andreas Engert; Elke Pogge von Strandmann
Journal:  Mol Ther       Date:  2013-03-05       Impact factor: 11.454

6.  Brentuximab vedotin for the treatment of patients with relapsed or refractory Hodgkin lymphoma after autologous stem cell transplantation.

Authors:  Panayotis Kaloyannidis; Mark Hertzberg; Kate Webb; Athanasios Zomas; Rudolf Schrover; Michael Hurst; Ian Jacob; Thalia Nikoglou; Joseph M Connors
Journal:  Br J Haematol       Date:  2019-10-06       Impact factor: 6.998

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.